论文部分内容阅读
目的:探讨鼻咽癌放疗后程同步辅以小剂量顺铂增敏的近期疗效,并与常规治疗和后程加速超分割放射治疗进行比较。方法:选取98例Ⅱ～Ⅳ期鼻咽癌患者,随机分为常规治疗组(简称T_1组,32例)、后程加速超分割治疗组(简称T_2组,32例)和顺铂加后程加速超分割治疗组(简称T_3组,34例),并对治疗效果进行比较。结果:T_1组鼻咽部肿瘤消除率为75.0%(24/32),颈部淋巴结消除率为87.5%(28/32);T_2组鼻咽部肿瘤消除率为87.5%(28/32),颈部淋巴结消除率为84.4%(27/32):T_3组鼻咽部肿瘤消除率为97.1%(33/34),颈部淋巴结消除率为91.2%(31/34)。进行两两比较,均为P<0.05,有统计学意义,疗效:T_3组>T_2组>T_1组。治疗副作用有增加(P>0.05),但无统计学意义。结论:小剂量顺铂加后程加速超分割治疗鼻咽癌,可以达到较常规治疗更好的近期治疗效果。
OBJECTIVE: To investigate the short-term curative effect of nasopharyngeal carcinoma after radiotherapy combined with low-dose cisplatin and sensitized with low-dose cisplatin and compared with routine therapy and accelerated accelerated radiofractionation. Methods: A total of 98 patients with stage Ⅱ ~ Ⅳ nasopharyngeal carcinoma were enrolled in this study. They were randomly divided into routine treatment group (T_1 group, 32 cases), post-accelerated hyperfractionation group (T_2 group, 32 cases) Accelerated hyperfractionation treatment group (T_3 group, 34 cases), and the treatment effect were compared. Results: The removal rate of nasopharyngeal tumor was 75.0% (24/32) in T 1 group, and the rate of cervical lymph node dissection was 87.5% (28/32). The removal rate of nasopharyngeal tumor in T 2 group was 87.5% (28/32) The rate of cervical lymph node dissection was 84.4% (27/32). The removal rate of nasopharyngeal tumor was 97.1% (33/34) in T 3 group and 91.2% (31/34) in cervical lymph node. All pairs of comparisons were P <0.05, with statistical significance, efficacy: T_3 group> T_2 group> T_1 group. Treatment side effects have increased (P> 0.05), but not statistically significant. Conclusion: The low-dose cisplatin plus accelerated hyperfractionated nasopharyngeal carcinoma treatment can achieve better than the conventional treatment of recent treatment.